Table 4. Univariate and multivariate analyses of overall survival and recurrence-free survival.
| Characteristic | Univariate analysis | Multivariate Cox regression analysis | |||
|---|---|---|---|---|---|
| Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | ||
| Age | 0.890 (0.513–1.544) | 0.679 | |||
| Histological type | 0.651 (0.334–1.269) | 0.208 | |||
| T stage | 1.648 (1.203–2.256) | 0.002* | 1.198 (0.820–1.749) | 0.350 | |
| N stage | 1.735 (1.365–2.205) | <0.001* | 1.532 (1.162–2.020) | 0.003* | |
| M stage | 13.409 (6.008–29.931) | <0.001* | 9.263 (3.852–22.278) | <0.001* | |
| pTNM stage | 2.593 (1.778–3.782) | <0.001* | |||
| ER | 0.524 (0.300–0.914) | 0.023* | 0.556 (0.232–1.331) | 0.187 | |
| PR | 0.553 (0.319–0.958) | 0.035* | 0.999 (0.419–2.382) | 0.998 | |
| HER2 | 1.882 (1.077–3.288) | 0.026* | 1.642 (0.897–3.008) | 0.108 | |
| Ki-67 | 1.934 (1.102–3.693) | 0.046* | 1.626 (0.815–3.243) | 0.167 | |
| Molecular subtype | 1.180 (0.997–1.425) | 0.086 | |||
| CEA | 2.636 (1.278–5.439) | 0.009* | 1.210 (0.538–2.725) | 0.645 | |
| CA153 | 1.724 (0.837–3.554) | 0.140 | |||
| CONUT | 2.520 (1.442–4.402) | 0.001* | 2.104 (1.172–3.779) | 0.013* | |
*P<0.05. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2; CEA, carcinoembryonic antigen; CA153, cancer antigen 153.